GlassScriptPhysician profile
Reza Mesbah
NPI 1235465089
$8,114.45
in general payments reported to CMS, 2019-2025
36 companies · $1,533 in 2025
The $1,533 reported for 2025 was more than what 90% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,077 · 2020: $1,715 · 2021: $1,461 · 2022: $561 · 2023: $173 · 2024: $595 · 2025: $1,533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,300.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,643.07 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,077.34 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $976.94 | 2019-2024 | Repatha, Otezla, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $743.43 | 2019-2025 | Synjardy, Jardiance |
| Lilly USA, LLC | $740.19 | 2019-2024 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $406.43 | 2019-2021 | |
| Glaxosmithkline, LLC. | $258.87 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $252.55 | 2020-2025 | Zoryve |
| Ardelyx, INC. | $212.59 | 2024-2025 | Ibsrela |
| Shield Therapeutics INC | $171.04 | 2024-2025 | |
| Astellas Pharma US INC | $160.25 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $158.30 | 2019-2025 | Dupixent |
| Esperion Therapeutics, INC. | $127.88 | 2020-2021 | |
| Abbvie INC. | $116.75 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $110.54 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $89.42 | 2022-2024 | |
| Genzyme Corporation | $86.46 | 2025 | |
| Lundbeck LLC | $86.29 | 2025 | Vyepti |
| Pfizer INC. | $76.96 | 2025 | |
| Novartis Pharmaceuticals Corporation | $66.08 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $61.11 | 2019-2021 | |
| Axsome Therapeutics, INC. | $57.49 | 2025 | Auvelity |
| Exact Sciences Corporation | $50.71 | 2023-2024 | Cologuard Collection Kit |
| Philips North America LLC | $46.09 | 2020 | |
| Horizon Therapeutics Plc | $45.12 | 2022 | |
| Amarin Pharma, INC. | $43.92 | 2020 | |
| Edwards Lifesciences Corporation | $33.79 | 2019 | |
| Phathom Pharmaceuticals, INC. | $33.75 | 2025 | Voquezna |
| Gilead Sciences, INC. | $33.14 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $28.36 | 2025 | Gemtesa |
| Medtronic, INC. | $25.55 | 2021 | |
| Aurinia Pharma U.S., INC. | $24.21 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $21.78 | 2020 | |
| Daiichi Sankyo INC. | $18.75 | 2022 | |
| Oxford Immunotec USA INC | $14.97 | 2022 | |
| Hologic Sales and Service, LLC | $14.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reza Mesbah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.